Cargando…
The evolving landscape of combination therapy for pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a progressively fatal disease, and the goal in treatment is to prevent disease progression. The standard of care often involves medications from multiple therapeutic classes, and there has been significant interest both in the choice of agent as well as the t...
Autores principales: | Griffin, Matthew, Trow, Terence K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933637/ https://www.ncbi.nlm.nih.gov/pubmed/27872176 http://dx.doi.org/10.1177/1753465816677485 |
Ejemplares similares
-
Macitentan for the treatment of pulmonary arterial hypertension
por: Kholdani, Cyrus A, et al.
Publicado: (2014) -
Endothelial dysfunction in pulmonary arterial hypertension: an evolving landscape (2017 Grover Conference Series)
por: Ranchoux, Benoît, et al.
Publicado: (2017) -
Lupus-Associated Pulmonary Arterial Hypertension: Variable Course and Importance of Prompt Recognition
por: Mensah, Kofi A., et al.
Publicado: (2015) -
The Place of Sulfonylureas in the Evolving Landscape of Combination Therapy
por: Yu, Miao
Publicado: (2020) -
Chronic thromboembolic pulmonary hypertension: the evolving treatment landscape
por: Kim, Nick H., et al.
Publicado: (2015)